Can KIADIS PHARMA N V ORDINARY SHARES NETHE (OTCMKTS:KIADF)’s Tomorrow Be Different? The Stock Had Decline in Shorts
Posted by Nellie Frank on January 17, 2019 at 2:29 pm
The stock of KIADIS PHARMA N V ORDINARY SHARES NETHE (OTCMKTS:KIADF) registered a decrease of 6.31% in short interest. KIADF’s total short interest was 89,100 shares in January as published by FINRA. Its down 6.31% from 95,100 shares, reported previously. With 100 shares average volume, it will take short sellers 891 days to cover their KIADF’s short positions.
It closed at $9.39 lastly. It is up 0.00% since January 17, 2018 and is . It has by 0.00% the S&P500.
Kiadis Pharma N.V., a clinical stage biopharmaceutical company, focuses on the research and development of cell immunotherapy products for the treatment of blood cancers and inherited blood disorders in the Netherlands. The company has market cap of $253.35 million. The firm focuses on therapeutic indications, including leukaemia, a common form of blood cancer; and thalassemia, an inherited blood disorder. It currently has negative earnings. The Company’s products comprise ATIR101 , a Phase II clinical trial product, which addresses the risk and limitations of hematopoietic stem cell transplantation in blood cancer; and ATIR201, which is in Phase I/II clinical development for inherited blood disorders with an initial focus on thalassemia.
Another recent and important Kiadis Pharma N.V. (OTCMKTS:KIADF) news was published by Seekingalpha.com which published an article titled: “KIADIS PHARMA N V 2017 Q4 – Results – Earnings Call Slides – Seeking Alpha” on April 16, 2018.
- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.